These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 18054518)

  • 1. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.
    Hersey P; Zhuang L; Zhang XD
    Int Rev Cytol; 2006; 251():131-58. PubMed ID: 16939779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
    Verhaegen M; Bauer JA; Martín de la Vega C; Wang G; Wolter KG; Brenner JC; Nikolovska-Coleska Z; Bengtson A; Nair R; Elder JT; Van Brocklin M; Carey TE; Bradford CR; Wang S; Soengas MS
    Cancer Res; 2006 Dec; 66(23):11348-59. PubMed ID: 17145881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative--Enhancement of both extrinsic and intrinsic apoptosis pathways.
    Berger A; Quast SA; Plötz M; Hein M; Kunz M; Langer P; Eberle J
    Biochem Pharmacol; 2011 Jan; 81(1):71-81. PubMed ID: 20858462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
    Kissel CK; Schadendorf D; Röckmann H
    Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
    Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
    Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
    Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
    Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth control of normal and malignant lymphocytes--cell death research from basic concepts to signal pathways and translation into the clinic.
    Debatin KM
    Klin Padiatr; 2009; 221(6):332-8. PubMed ID: 19890783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting apoptosis as an approach for gastrointestinal cancer therapy.
    Qiao L; Wong BC
    Drug Resist Updat; 2009 Jun; 12(3):55-64. PubMed ID: 19278896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for uveal melanoma.
    Triozzi PL; Eng C; Singh AD
    Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapy for melanoma: current reality and future options.
    Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
    Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma.
    Hersey P
    Curr Opin Oncol; 2006 Mar; 18(2):189-96. PubMed ID: 16462190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Kinase inhibitors for the therapy of malignant melanoma].
    Becker JC; Schrama D; Bröcker EB; Houben R
    J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis-based therapies and drug targets.
    Fischer U; Schulze-Osthoff K
    Cell Death Differ; 2005 Aug; 12 Suppl 1():942-61. PubMed ID: 15665817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targets in melanoma from angiogenesis to apoptosis.
    Sosman JA; Puzanov I
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR; Vega MI; Bonavida B
    Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of apoptosis pathways in cancer.
    Ziegler DS; Kung AL
    Curr Opin Oncol; 2008 Jan; 20(1):97-103. PubMed ID: 18043263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.
    Goldsmith KC; Hogarty MD
    Cancer Lett; 2005 Oct; 228(1-2):133-41. PubMed ID: 15927359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.